304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2022-12-27

Henlius and Fosun Pharma Entered into an Exclusive License Agreement for HANSIZHUANG in the US
2022-12-15

First Patient Dosed in a Phase 1 Clinical Study of Henlius Novel Anti-GARP and Anti-PD-1 Dual mAb Therapy in Australia
2022-12-15

HANSIZHUANG Granted Orphan Drug Designation in the European Union for Small Cell Lung Cancer
2022-12-09

First Patient Dosed in the Phase 1 Clinical Trial of Henlius’ Novel Anti-TIGIT Fc Fusion Protein HLX53
2022-12-05

Consul General in San Francisco visited Henlius US Innovation Centre
2022-12-02

The Phase 3 Clinical Study Results of Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of ESCC Released at ESMO Asia Congress 2022
2022-12-02

The Updated Results of Phase 3 Clinical Study of Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of ES-SCLC Released at ESMO Asia Congress 2022
2022-12-02

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Novel Anti-GARP mAb HLX60
2022-11-29

First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US